ARTICLE | Deals
Who’ll buy uniQure now?
Even without its lead hemophilia program, the gene therapy company could make for an attractive takeout target
June 27, 2020 1:46 AM UTC
UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target.
Investors immediately soured on Wednesday’s deal in which uniQure N.V. (NASDAQ:QURE) granted CSL Ltd. (ASX:CSL) exclusive, worldwide rights to etranacogene dezaparvovec. UniQure’s shares fell 22% on Thursday, the first trading session after the deal was announced...